DarioHealth director Lawrence Leisure retires

DarioHealth Corp. discloses the retirement of board member Lawrence Leisure, citing personal reasons and no disagreements with the company.

Available on EDGAR 09/04/2026 - 04:07 PM EDT Accepted by SEC EDGAR 09/04/2026 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

DarioHealth Corp. (DRIO) reports that Lawrence Leisure has retired from its Board of Directors, effective September 2, 2026, for personal reasons. The company states that his decision to retire did not result from any disagreement regarding its operations, policies, or practices. The report is signed by Chief Financial Officer, Treasurer and Secretary Chen Franco‑Yehuda.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Effective date of director retirement: September 2, 2026 Report signature date: September 4, 2026 Commission File Number: 001-37704

3 metrics

Effective date of director retirement September 2, 2026 Retirement of director Lawrence Leisure from the Board of Directors

Report signature date September 4, 2026 Date DarioHealth Corp. signed the current report on Form 8-K

Commission File Number 001-37704 DarioHealth Corp. Exchange Act registration reference

Key Terms

Emerging growth company, Board of Directors, Nasdaq Capital Market LLC

3 terms

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Board of Directors financial

"notified the Board of Directors of DarioHealth Corp."

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

Nasdaq Capital Market LLC market

"Common Stock, par value $0.0001 per share ... The Nasdaq Capital Market LLC"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did DarioHealth Corp. (DRIO) announce on September 2, 2026?

DarioHealth Corp. announced that Lawrence Leisure retired from its Board of Directors, effective September 2, 2026. The company stated that his retirement was for personal reasons and not due to any disagreement regarding its operations, policies, or practices.

When did DarioHealth (DRIO) director Lawrence Leisure’s retirement become effective?

The retirement of director Lawrence Leisure became effective on September 2, 2026. DarioHealth Corp. disclosed that he notified the Board on that date and that his departure was for personal reasons.

Did DarioHealth Corp. (DRIO) report any disagreement related to Lawrence Leisure’s retirement?

No. DarioHealth Corp. stated that Lawrence Leisure’s decision to retire was not the result of any disagreement with the company on matters relating to its operations, policies, or practices.

Who signed the September 2026 Form 8-K for DarioHealth Corp. (DRIO)?

The Form 8-K was signed by Chen Franco‑Yehuda, who is identified as the company’s Chief Financial Officer, Treasurer and Secretary, on behalf of DarioHealth Corp.

What is the principal executive office address of DarioHealth Corp. (DRIO)?

DarioHealth Corp.’s principal executive offices are located at 322 W. 57th St., #33B, New York, New York 10019, as stated in the report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001533998 0001533998 2026-09-02 2026-09-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 2, 2026

DARIOHEALTH CORP.

(Exact name of registrant as specified in its charter)

Delaware		001-37704		45-2973162
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

322 W. 57th St., #33B
New York, New York 10019

(Address of Principal Executive Offices)

972- 4-770-6377

(Issuer’s telephone number)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which  registered
Common Stock, par value $0.0001 per share		DRIO		The Nasdaq Capital Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 2, 2026, Lawrence Leisure notified the Board of Directors (the “Board”) of DarioHealth Corp. (the “Company”) of his decision to retire from the Board, effective September 2, 2026, for personal reasons. Mr. Leisure’s decision to retire was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 4, 2026	DARIOHEALTH CORP.
	By:	/s/ Chen Franco-Yehuda
	Name:	Chen Franco-Yehuda
	Title:	Chief Financial Officer, Treasurer and Secretary

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.8 KB